Francesca De Felice1, Daniela Musio, Raffaele Cassese, Giovanni Luca Gravina, Vincenzo Tombolini.
Abstract
BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response.
OBJECTIVE: To clarify the role of immune check point inhibitors in GBM management.
METHODS: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials. gov and abstracts recently presented at international congresses.
RESULTS: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management.
CONCLUSION: Immune check-point inhibitors should be considered a promising treatment option in GBM. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent brain tumor. Despite recent advances in treatment approaches the prognosis remains poor, with a median overall survival of 14.6 months. Immunotherapy is the subject of ongoing research and its benefit is becoming evident in other malignancies. Immune check-points such as cytotoxic T lymphocyte associated antigen 4 (CTLA-4), programmed cell death receptor (PD-1) and indoleamine 2,3-dioxygenase (IDO) reduce immune response.
OBJECTIVE: To clarify the role of immune check point inhibitors in GBM management.
METHODS: Preclinical and clinical trials of immune check-point inhibitors in GBM were obtained by searching for English peer-reviewed articles on PubMed databases, trials registered on clincaltrials. gov and abstracts recently presented at international congresses.
RESULTS: Immune check point inhibitors may be of critical importance for the design of future immunotherapy approaches in GBM management.
CONCLUSION: Immune check-point inhibitors should be considered a promising treatment option in GBM. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities:
Keywords:
CTLA-4; Immunotherapy; PD-1; check-point; glioblastoma multiforme; immune system; ipilimumab; radiotherapy
Mesh：
Substances：
Year: 2017
PMID： 27528363 DOI： 10.2174/1568009616666160813183738
Source DB: PubMed Journal: Curr Cancer Drug Targets ISSN： 1568-0096 Impact factor: 3.428